ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) shares have continued their recent momentum with a 27% gain in the last month alone. But the last month did very little to improve the 55% share price decline over the last year.
After such a large jump in price, ImmuneOnco Biopharmaceuticals (Shanghai)’s price-to-sales (or “P/S”) ratio of 33.5x might make it look like a strong sell right now compared to other companies in the Biotechs industry in Hong Kong, where around half of the companies have P/S ratios below 10.9x and even P/S below 4x are quite common. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
See our latest analysis for ImmuneOnco Biopharmaceuticals (Shanghai)
What Does ImmuneOnco Biopharmaceuticals (Shanghai)’s Recent Performance Look Like?
ImmuneOnco Biopharmaceuticals…
